Loading...
Enzalutamide for the treatment of prostate cancer
INTRODUCTION: The FDA approval of docetaxel for metastatic castration-resistant prostate cancer (mCRPC) in 2005 marked a major milestone – as it was the first approved agent for this disease that demonstrated a survival advantage in phase III assessment in this disease. Since 2009, several other age...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845878/ https://ncbi.nlm.nih.gov/pubmed/23441761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2013.775251 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|